Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.
Susan C. Modesitt, MD, FACS, FACOG
Advertisement
Articles by Susan C. Modesitt, MD, FACS, FACOG
Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.
Advertisement
Latest Updated Articles
Inheritance Matters: The Race to Prevent New Ovarian Cancer CasesJanuary 31st 2018
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5